Capricor Therapeutics (CAPR) Competitors

$5.56
+0.15 (+2.77%)
(As of 09:45 AM ET)

CAPR vs. ALIM, GLSI, ME, GOSS, TRVI, VERU, VACC, ATOS, ACET, and OGI

Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Alimera Sciences (ALIM), Greenwich LifeSciences (GLSI), 23andMe (ME), Gossamer Bio (GOSS), Trevi Therapeutics (TRVI), Veru (VERU), Vaccitech (VACC), Atossa Therapeutics (ATOS), Adicet Bio (ACET), and Organigram (OGI). These companies are all part of the "pharmaceutical preparations" industry.

Capricor Therapeutics vs.

Capricor Therapeutics (NASDAQ:CAPR) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Alimera Sciences received 14 more outperform votes than Capricor Therapeutics when rated by MarketBeat users. However, 62.57% of users gave Capricor Therapeutics an outperform vote while only 57.72% of users gave Alimera Sciences an outperform vote.

CompanyUnderperformOutperform
Capricor TherapeuticsOutperform Votes
341
62.57%
Underperform Votes
204
37.43%
Alimera SciencesOutperform Votes
355
57.72%
Underperform Votes
260
42.28%

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are owned by institutional investors. 12.0% of Capricor Therapeutics shares are owned by insiders. Comparatively, 31.4% of Alimera Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Capricor Therapeutics had 8 more articles in the media than Alimera Sciences. MarketBeat recorded 10 mentions for Capricor Therapeutics and 2 mentions for Alimera Sciences. Capricor Therapeutics' average media sentiment score of 0.47 beat Alimera Sciences' score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Capricor Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alimera Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alimera Sciences has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capricor Therapeutics$25.18M6.77-$22.29M-$0.87-6.22
Alimera Sciences$80.75M2.26-$20.13M-$2.16-1.62

Capricor Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 343.62%. Alimera Sciences has a consensus target price of $7.50, indicating a potential upside of 114.90%. Given Capricor Therapeutics' higher probable upside, research analysts plainly believe Capricor Therapeutics is more favorable than Alimera Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capricor Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alimera Sciences
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Alimera Sciences has a net margin of -24.93% compared to Capricor Therapeutics' net margin of -88.52%. Alimera Sciences' return on equity of -130.90% beat Capricor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capricor Therapeutics-88.52% -299.67% -45.54%
Alimera Sciences -24.93%-130.90%-10.22%

Capricor Therapeutics has a beta of 3.99, indicating that its stock price is 299% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500.

Summary

Alimera Sciences beats Capricor Therapeutics on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAPR vs. The Competition

MetricCapricor TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$170.43M$4.81B$4.96B$7.63B
Dividend YieldN/A3.20%2.93%3.94%
P/E Ratio-6.2212.97218.7819.17
Price / Sales6.77302.932,380.9787.90
Price / CashN/A29.4048.6835.33
Price / Book7.415.284.634.26
Net Income-$22.29M$129.27M$103.91M$214.06M
7 Day Performance7.98%0.69%0.75%1.88%
1 Month Performance-20.32%-11.74%-8.16%-5.70%
1 Year Performance39.07%-4.68%3.66%6.72%

Capricor Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALIM
Alimera Sciences
1.6987 of 5 stars
$3.58
+1.1%
$7.50
+109.5%
+90.7%$187.41M$80.75M-1.66154
GLSI
Greenwich LifeSciences
2.2997 of 5 stars
$14.42
+1.1%
$36.00
+149.7%
+22.5%$185.30MN/A-20.313Short Interest ↑
ME
23andMe
0.5967 of 5 stars
$0.39
-2.5%
$1.75
+348.6%
-76.4%$188.39M$299.49M-0.35769Gap Up
GOSS
Gossamer Bio
3.8757 of 5 stars
$0.82
-4.6%
$7.65
+832.0%
-48.2%$185.16MN/A-0.59135Gap Up
TRVI
Trevi Therapeutics
2.4286 of 5 stars
$2.67
-5.3%
$8.50
+218.9%
-19.2%$183.78MN/A-9.1925
VERU
Veru
0.8661 of 5 stars
$1.26
-18.2%
$3.33
+165.6%
+0.0%$183.71M$16.30M-1.67189Gap Up
VACC
Vaccitech
0 of 5 stars
$2.53
-4.2%
$7.63
+201.4%
+8.2%$192.74M$13.42M-1.7733Gap Up
ATOS
Atossa Therapeutics
1.2676 of 5 stars
$1.54
-9.9%
$4.50
+192.2%
+139.4%$192.96MN/A-6.4211Short Interest ↑
Gap Down
ACET
Adicet Bio
1.8709 of 5 stars
$2.19
-0.5%
$12.83
+486.0%
-71.2%$179.91M$24.99M-0.66143Gap Up
OGI
Organigram
0.1403 of 5 stars
$1.88
flat
N/A-7.0%$194.02M$120.01M-2.35984Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:CAPR) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners